People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Biotech / Pharma, Other Technology, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| GENEOS Therapeutics, Inc. | — | Biotechnology | Series B | $37.1M | $61.0M | 2022 |
| Lyric Pharmaceuticals Inc. | — | Pharmaceuticals | Series B | $26.8M | $910.8M | 2015 |
| Ten Bay Bio, Inc. | — | Biotech / Pharma | Series A | $11.5M | $58.4M | 2024 |
| Molecular Templates, Inc. | — | Other Technology | Series A | $9.4M | $194.2M | 2011 |
| Glyscend, Inc. | — | Other Health Care | Series A | $4.8M | $96.9M | 2020 |
| Abvitro Inc | — | Other | Seed | $2.6M | $34.8M | 2012 |
| Terapio Corp | — | Other Health Care | Pre-Seed | $574K | $17.7M | 2009 |
Casey Cunningham at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Casey Cunningham on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Lalande | 3 | 8 |
| Timothy Sullivan | 1 | 16 |
| Niall O'Donnell | 1 | 7 |
| Joseph Kim | 1 | 5 |
| Joe Cunningham | 1 | 5 |
| Paul Weiss | 1 | 5 |
| Jason Hong | 1 | 4 |
| Dennis McWilliams | 1 | 4 |
| Tim Mayleben | 1 | 4 |
| Leighton Read | 1 | 4 |
| Jason Kim | 1 | 3 |
| Mirza Cifric | 1 | 3 |
| Curt Bilby | 1 | 2 |
| Steven Gullans | 1 | 2 |
| Phillip Sanger | 1 | 2 |
| Louis Bock | 1 | 2 |
| Ted Fjallman | 1 | 2 |
| Sanford Zweifach | 1 | 1 |
| Stephen Howard | 1 | 1 |
| David Wurtman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.